0B68 Schnell, Matthias J. - Thomas Jefferson University - Thomas Jefferson University
mjs106

Matthias J. Schnell, PhD

Contact Dr. Schnell

233 South Tenth Street
Bluemle Life Sciences Building, Room 531
Philadelphia, PA 19107-5541

(215) 503-4634
(215) 503-5393 fax

Most Recent Peer-reviewed Publications

  1. Everything You Always Wanted to Know about Rabies Virus (But 1F19 Were Afraid to Ask)
  2. Human polyclonal antibodies produced through DNA vaccination of transchromosomal cattle provide mice with post-exposure protection against lethal zaire and Sudan ebolaviruses
  3. Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics
  4. Rhabdovirus-based vaccine platforms against henipaviruses
  5. Controlled viral glycoprotein expression as a safety feature in a bivalent rabies-ebola vaccine
  6. Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses
  7. Safety and serological response to a matrix gene-deleted rabies virus-based vaccine vector in dogs
  8. Small-molecule probes targeting the viral PPxY-host nedd4 interface block egress of a broad range of RNA viruses
  9. Interspecies protein substitution to investigate the role of the lyssavirus glycoprotein
  10. Rabies virus (RV) glycoprotein expression levels are not critical for pathogenicity of RV
  11. Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity
  12. Rabies virus infection induces type I interferon production in an IPS-1 dependent manner while dendritic cell activation relies on IFNAR signaling.
  13. Induction of neutralizing antibody responses to anthrax protective antigen by using influenza virus vectors: Implications for disparate immune system priming pathways
  14. Rabies virus infection induces type I interferon production in an IPS-1 dependent manner while dendritic cell activation relies on IFNAR signaling
  15. Characterization of a single-cycle rabies virus-based vaccine vector
  16. A novel composite immunotoxin that suppresses rabies virus production by the infected cells
  17. Attenuation of rabies virulence: Takeover by the cytoplasmic domain of its envelope protein
  18. The cell biology of rabies virus: Using stealth to reach the brain
  19. Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIVmac251 challenge
  20. Replication-deficient rabies virus-based vaccines are safe and immunogenic in mice and nonhuman primates
0